section name header

Pronunciation

STRON-tee-um eighty-nine KLOH-ride

Classifications

Therapeutic Classification: nonopioid analgesics

Pharmacologic Classification: radiopharmaceuticals

Indications

REMS


Action

  • Preferentially taken up by bone tumors and metastatic bone lesions, where selective irradiation takes place.
Therapeutic effects:
  • Decreased pain from bony metastases. Because of delayed onset, adequate analgesia should be provided until effects of strontium are evident.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Selectively localized in and retained by metastatic bone lesions. Excreted in breast milk.

Metabolism/Excretion: 67% excreted in urine, 33% in feces.

Half-Life: (physical half-life) 50.5 days.

Time/Action Profile

(pain relief)

ROUTEONSETPEAKDURATION
IV7–20 daysvariable6 mo (range 4–12 mo)

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Hemat: anemia, neutropenia, thrombocytopenia

MS: transient increase in bone pain

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Metastron